SC18: Clinical Prospects of Cancer Immunotherapy
Thursday, May 4
5:45 - 8:15 PM | Dinner Included
Instructor
Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center
Summary
This short course will review the development of immunotherapy-based approaches in the treatment of cancer as well as the current and emerging targets for cancer immunotherapies. The efficacy, toxicity and challenges associated with the use of immunotherapeutic agents in oncologic practice will also be discussed along with the role of biomarker development in predicting treatment outcomes.
Topics covered in this course include:
- History of immunotherapy in cancer
- Rationale for using immunotherapy against cancer
- Immunotherapy approaches in treating cancer
- Current targets for cancer immunotherapies
- Emerging targets for cancer immunotherapies
- Revolutionary role of checkpoint inhibitors
- Clinical efficacy of immunotherapy-based anticancer approaches
- Toxicity and challenges encountered in oncologic practice
- Development of biomarkers to predict response
- Response evaluation with immunotherapeutic agents
- Clinical drug development
- Upcoming clinical data on immune checkpoint inhibitors
Instructor Bio:
Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center
Gaurav Goel, MD is a medical oncologist, Assistant Professor of Medicine in the Division of Medical Oncology at the Markey Cancer Center, University of Kentucky in Lexington, Kentucky. After earning his medical degree from the University of Delhi in India, Dr. Goel completed his internship and residency in Internal medicine at Montefiore Medical Center in New York. He then joined University of Pittsburgh Cancer Institute as a clinical and research fellow in medical oncology and hematology. Dr. Goel has authored several scholarly peer-reviewed articles including research papers, reviews and book chapters, and has served as an investigator on multiple clinical research studies. He has a special interest in the treatment of gastrointestinal cancers, with a special research focus on immunotherapeutic approaches for the treatment of cancer. One of his recent publications from his lab-based research work in immunotherapy was titled, 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016;4:65. Dr. Goel is also a member of several professional organizations, including the the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research.